Qutenza(capsaicin)
Qutenza (capsaicin) is a small molecule pharmaceutical. Capsaicin was first approved as Qutenza on 2009-05-15. It is used to treat diabetic neuropathies, herpes zoster, and neuralgia in the USA. It has been approved in Europe to treat neuralgia. The pharmaceutical is active against transient receptor potential cation channel subfamily V member 1. In addition, it is known to target voltage-gated potassium channel KCNC1, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 2, cystic fibrosis transmembrane conductance regulator, and potassium voltage-gated channel subfamily A member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Qutenza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Capsaicin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QUTENZA | Averitas Pharma | N-022395 RX | 2009-11-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 0.025% capsaicin pain relief patch | unapproved drug other | 2025-06-10 |
| 1st medxpatch | C200263 | 2024-10-31 |
| 2-count heat patches | C200263 | 2024-12-19 |
| 3% menthol plus 0.083% capsaicin pain relief patch | unapproved drug other | 2025-06-10 |
| advil targeted relief | C200263 | 2024-02-08 |
| ageranium patch | OTC monograph not final | 2017-12-29 |
| alivio medicated pain | OTC monograph not final | 2015-01-21 |
| allevess | OTC monograph not final | 2015-12-02 |
| ameripatch | OTC monograph not final | 2015-11-18 |
| arth arrest | C200263 | 2023-11-11 |
Show 232 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neuralgia | EFO_0009430 | D009437 | — |
| diabetic neuropathies | EFO_1000783 | D003929 | — |
| herpes zoster | EFO_0006510 | D006562 | B02 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CAPSAICIN, QUTENZA, AVERITAS | |||
| 2023-07-17 | I-838 | ||
ATC Codes
M: Musculo-skeletal system drugs
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AB: Capsaicin and similar agents
— M02AB01: Capsaicin
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BX: Other local anesthetics in atc
— N01BX04: Capsaicin
HCPCS
Code | Description |
|---|---|
| J7336 | Capsaicin 8% patch, per square centimeter |
Clinical
Clinical Trials
289 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 1 | 1 | — | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | 1 | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Capsaicin |
| INN | capsaicin |
| Description | Capsaicin is a capsaicinoid. It has a role as a non-narcotic analgesic, a voltage-gated sodium channel blocker and a TRPV1 agonist. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 404-86-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL294199 |
| ChEBI ID | 3374 |
| PubChem CID | 1548943 |
| DrugBank | DB06774 |
| UNII ID | S07O44R1ZM (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TRPV6
TRPV6
KCNC1
KCNC1
Organism
Homo sapiens
Gene name
TRPV6
Gene synonyms
ECAC2
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily V member 6
Protein synonyms
Alu-binding protein with zinc finger domain, Calcium transport protein 1, calcium transporter-like protein, CaT-L, CaT-like, CaT1, ECaC2, epithelial apical membrane calcium transporter/channel CaT1, Epithelial calcium channel 2
Uniprot ID
Mouse ortholog
Trpv6 (64177)
transient receptor potential cation channel subfamily V member 6 (Q91WD2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Capsaicin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 36,879 documents
View more details
Safety
Black-box Warning
Black-box warning for: Capsinac, Diclosaicin, Diclotral pak, Flexipak, Iclofenac cp, Lextol, Naprotin, Ziclopro
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,762 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use